Compare First Solar, Inc. (FSLR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? First Solar, Inc. trades at $213.8 (market cap $24.05B), while State Street SPDR S&P Biotech ETF trades at $152.76. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals.
| FSLR | XBI | |
|---|---|---|
Market Cap | $24.05B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $318.30 | $164.28 |
52-Week Low | $166.82 | $85.16 |
Enterprise Value | $22.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $220.58, down 0.2% on the day, with a bearish technical signal driven by moving averages. The company shows strong fundamentals with a P/E of 14.46, net income margin of 30.73%, and robust cash flow from operations of $2.06B in 2025. Recent earnings beat in Q1 2026 but missed in prior quarters. Multiple class-action lawsuits filed in July 2026 allege securities fraud, creating near-term legal overhang.
The stock presents a mixed outlook: solid profitability and analyst consensus price target of $275.17 suggest upside, but legal risks and bearish technicals weigh. Investors face tension between strong financial health and potential volatility from litigation outcomes.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
